SAN FRANCISCO -- First-line treatment with targeted therapies plus chemotherapy offered overall response benefits in BRAF V600E-mutant metastatic colorectal cancer (mCRC), according to the ...

Braftovi is a small molecule inhibitor of proteins with the BRAF V600E mutation, which can lead to activation of signaling pathways that drive certain cancers, including colorectal cancer.

In this video, Arvind N. Dasari, MD, MS, discussed the phase 3 results from the BREAKWATER trial presented at ASCO Gastrointestinal Cancers Symposium.

No writing assistance was utilized in the production of this manuscript. BRAF, a member of a serine/threonine kinase protein family, serves as an immediate downstream effector of RAS in the MAPK ...

BRAF V600E-mutant metastatic CRC is associated with poor clinical outcomes, with a median overall survival of 17 months. Factors influencing overall survival include metastasectomy and ECOG ...

Braftovi combo improved objective response rate to 60.9% vs. 40% with standard chemotherapy in BRAF V600E-mutant mCRC. Median response duration was 13.9 months vs. 11.1 months, with 22.4% ...

We played a major role in characterising the BRAF gene and its role in cancer, increasing our understanding of malignant melanoma. Our work on the gene and the structure of the BRAF protein ...